Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
Operating Income
Samsung Biologics Co Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
|
Operating Income
₩1.1T
|
CAGR 3-Years
56%
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Operating Income
-₩15.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Operating Income
-₩1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Operating Income
₩33.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Operating Income
-₩8.4B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Operating Income
-₩80.8B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-29%
|
See Also
What is Samsung Biologics Co Ltd's Operating Income?
Operating Income
1.1T
KRW
Based on the financial report for Dec 31, 2023, Samsung Biologics Co Ltd's Operating Income amounts to 1.1T KRW.
What is Samsung Biologics Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
82%
Over the last year, the Operating Income growth was 13%. The average annual Operating Income growth rates for Samsung Biologics Co Ltd have been 56% over the past three years , 82% over the past five years .